RxDoctor Payments Data

Taylor Reardon, PA

Physician Assistant · Syracuse, NYNPI 1154865913

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Mayne Pharma Commercial LLC at 24.9% of the total. Reporting peaked in 2023 at $299 and has fallen 72.6% since, to $82 in 2024.

$487in general payments, 2019–2025

Across 27 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$121
  • AbbVie$68
  • Bayer$60
  • Pfizer$40
  • Agile Therapeutics, Inc.$35
  • Boston Scientific$31
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$487 in reported general payments places this provider in the 65th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York →

Medicare billing

Part B allowed, 2024
$1,614
Medicare patients
18
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron12$5,423
Estradiol43$4,394
Darifenacin ErDarifenacin Hydrobromide11$1,922
Alendronate Sodium25$457
Metronidazole12$382
Nystatin15$118

Paid to pharmacies, not to this prescriber.

Other physician assistant in Syracuse

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →